期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

淀粉样蛋白正电子发射断层扫描成像在阿尔茨海默病诊断中价值 被引量：1

Value of amyloid positron emission tomography imaging to the diagnosis of Alzheimers disease
原文传递
导出
摘要 淀粉样蛋白正电子发射断层扫描(positron emission tomography,PET)成像能有效显示活体内神经炎性斑块含量。淀粉样蛋白PET成像对鉴别阿尔茨海默病(Alzheimess disease,AD)与健康对照者的特异性较结构性核磁共振成像高,鉴别AD和健康对照者的灵敏度高于氟代脱氧葡萄糖PET成像,且有更高可靠性。AD患者淀粉样蛋白PET成像与脑脊液A-beta 42的结果高度一致。本文就淀粉样蛋白PET成像技术在AD临床诊断中应用的研究进展作一综述。 Amyloid positron emission tomography（PET）is a valid in vivo marker of neuritic plaque load.The specificity of amyloid PET for discriminating Alzheimers disease（AD）from healthy controls is higher than that of structural MRI,and the sensitivity is also higher than that of fluorodeoxyglucose-PET,with a high interreader reliability.There is a high concordance between the results of amyloid PET and cerebrospinal fluid A-beta 42 for AD patients.This paper reviews the current research progression of amyloid PET in the diagnosis of AD.
作者 吕梦娜 张洪
机构地区 武汉大学中南医院神经内科
出处 《中华实用诊断与治疗杂志》 2015年第4期328-329,332,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 阿尔茨海默病 淀粉样蛋白 正电子发射断层扫描成像 Alzheimer＇s disease amyloid positron emission tomography
分类号 R749.16 [医药卫生—神经病学与精神病学] R814.42 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献20

  • 1张洪,章军建.阿尔茨海默病早期诊断与治疗[J].中华实用诊断与治疗杂志,2013,27(6):523-525. 被引量：29
  • 2张洪,章军建.血管性认知功能障碍防治进展[J].中华实用诊断与治疗杂志,2013,27(11):1048-1050. 被引量：13
  • 3Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010[J]. J Neuropathol Exp Neurol, 2012,71 (4) : 266-273.
  • 4Vandenberghe R, Nelissen N, Salmon E, et al. Binary classification of 18F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI [ J ]. Neuroimage, 2012,64 (1) :517-525.
  • 5Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-b plaques: a prospective cohort study[J]. Lancet Neurol, 2012,11(8) : 669-678.
  • 6Rinne JO, Wong DF, Wolk DA, et al. 18F-flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid h detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies[J]. Acta Neuropathol, 2012,124 (6) :833-845.
  • 7Thurfjell L, Lotjonen J, Lundqvist R, et al. Combination of biomarkers: PET 18F-flutemetamol imaging and structural MRI in dementia and mild cognitive impairment[J]. Neurodegener Dis, 2012,10(1/4) :246-249.
  • 8Duara R, Loewenstein DA, Shen Q, et al. Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease [J]. Alzheimers Dement, 2013,9(3) :295-301.
  • 9Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls[J]. J Geriatr Psychiatry Neurol, 2010,23 (3):185-198.
  • 10Rabinoviei GD, Rosen HJ, Alkalay A, etal. Amyloid vs FDG- PET in the differential diagnosis of AD and FTLD [J]. Neurology, 2011,77 (23) : 2034-2042.

二级参考文献42

  • 1Mayeux R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci, 2003,26 (1) 81-104.
  • 2Jun G, Naj A C, Beecham G W, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes[J]. Arch Neurol, g010,67(12) :1473-1484.
  • 3Chu L W, Tam S, Wong R L, et al. Bioavailable testosterone predicts a lower risk d Alzheimer's disease in older men[J]. J Alzheimers Dis,2010,21(4) : 1335-1345.
  • 4Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal[J]. J Neurochem, 2009,110(4) : 1129 1134.
  • 5Chiu K C, Chu L W, Chung C P, et al. Clinical features of Alzheimer's disease in a regional memory clinic in Hong Kong [J]. J Hong KongGeriatr Soc,2002,11(1):21-27.
  • 6McKhann G M, Knopman D S, Chertkow H, et aZ. The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging- Alzheimer's Association Workgroups on Aiagnostic Duidelines for Alzheimer's Disease[J]. Alzheimers Dement, 2011,7 ( 1 ) : 263-269.
  • 7Mak H K, Zhang Z, Yau K K, et al. Efficaey of voxel based morphometry with DARTEL and standard registration as imaging biomarkers in Alzheimer's disease patients and cognitively normal older adults at 3.0 Tesla MR imaging[J]. J Alzheimers Dis,2011,23(4) :655 664.
  • 8Tartaglia M C, Rosen H J, Miller 13 L. Neuroimaging in dementia[J]. Neurotherapeutics, 2011,8 (1) : 82-92.
  • 9Morris J C, Roe C M, Grant E A, etal. Pittsburgh compound B imaging and prediction of progression {rom cognitive normality to symptomatic Alzheimer disease[J]. Arch Neurol, 2009,66(12) 1469-1475.
  • 10Fjell A M, Walhovd K B, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease[J]. J Neurosci, 2010,30(6) :2088-2101.

共引文献38

同被引文献6

引证文献1

二级引证文献10

中华实用诊断与治疗杂志
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部